Top Markets
#1 Black Phoenix Black Phoenix +734.77%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.07%
#3 TENDIES TENDIES +19.72%
#4 Biconomy Biconomy +19.10%
#5 THORChain THORChain +18.60%
#6 MetaDAO MetaDAO +18.10%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +18.08%
#8 THORChain Yield THORChain Yield +13.81%
#9 Derive Derive +10.27%
#10 Bless Bless +9.92%
Coin of the day
Black Phoenix Black Phoenix
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Keymed Biosciences Inc. Keymed Biosciences Inc.

Keymed Biosciences Inc.

2162
Hisse Senetlerindeki Sıralama #5165
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Hisse Fiyatı
$9.91
Piyasa Değeri
$2.92B
Değişim (1 gün)
-3.25%
Değişim (1 yıl)
16.09%
Ülke
CN
Ticaret Keymed Biosciences Inc. (2162)

Kategori

Healthcare
Keymed Biosciences Inc. (2162) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $10.18 - 2026-08-01

Gün sonu en düşük fiyat: $8.48 - 2021-07-01
Keymed Biosciences Inc. için hisse fiyatı geçmişi: 2021 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2026 (TTM) 16.02%
2025 52.92%
2024 -27.80%
2023 2.46%
2022 25.70%
2021 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.18 -12.97%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.08%
CH